The anaphase-promoting complex/cyclosome (APC/C) is an ubiquitin ligase that functions during mitosis. Here we identify the transcriptional regulator, transcriptional intermediary factor 1g, TIF1g, as an APC/C-interacting protein that regulates APC/C function. TIF1g is not a substrate for APC/C-dependent ubiquitylation but instead, associates specifically with the APC/C holoenzyme and Cdc20 to affect APC/C activity and progression through mitosis. RNA interference studies indicate that TIF1g knockdown results in a specific reduction in APC/C ubiquitin ligase activity, the stabilization of APC/C substrates, and an increase in the time taken for cells to progress through mitosis from nuclear envelope breakdown to anaphase. TIF1g knockdown cells are also characterized by the inappropriate presence of cyclin A at metaphase, and an increase in the number of cells that fail to undergo metaphase-to-anaphase transition. Expression of a small interfering RNA-resistant TIF1g species relieves the mitotic phenotype imposed by TIF1g knockdown and allows for mitotic progression. Binding studies indicate that TIF1g is also a component of the APC/C-mitotic checkpoint complex (MCC), but is not required for MCC dissociation from the APC/C once the spindle assembly checkpoint (SAC) is satisfied. TIF1g inactivation also results in chromosome misalignment at metaphase and SAC activation; inactivation of the SAC relieves the mitotic block imposed by TIF1g knockdown. Together these data define novel functions for TIF1g during mitosis and suggest that a reduction in APC/C ubiquitin ligase activity promotes SAC activation.
INTRODUCTION
The anaphase-promoting complex/cyclosome (APC/C) is a multiprotein E3 ubiquitin ligase complex that coordinates mitotic progression and exit through targeting substrates such as securin and cyclin B1 for proteasomal-mediated degradation. 1,2 APC/C activity is controlled by the cell cycle-dependent recruitment of one of two activators, Cdc20 or Cdh1, to specific APC/C proteins. 1, 2 Cdc20 and Cdh1 also serve in conjunction with particular APC/C subunits to bind substrates. 1,2 APC/C-Cdc20 regulates metaphaseto-anaphase transition primarily by targeting the separase inhibitor, securin, for degradation. 1 APC/C-Cdc20 activity is tightly controlled by the spindle assembly checkpoint (SAC), which monitors microtubule attachment to kinetochores and ensures the fidelity of sister chromatid segregation at anaphase. 2, 3 When the SAC is activated by the presence of unattached kinetochores, SAC components MAD2, BubR1 and Bub3 all serve to inhibit APC/C-Cdc20 activity, and metaphase-to-anaphase transition. 2,3 APC/C-Cdc20 and APC/C-Cdh1 are also regulated by the transcriptional coactivators CBP and p300, which bind to APC/C subunits APC5 and APC7, through interaction domains conserved in adenovirus E1A. 4, 5 The DNA damage response protein, MDC1, also regulates APC/C-Cdc20 activity during mitosis and functions independently of SAC and DNA damage response pathways, to facilitate Cdc20 association with the APC/C. 6 TIF1g, also known as TRIM33 and hEctodermin, is a member of the Tripartite Motif/RING finger, B-boxes and a coiled-coil domain (TRIM/RBCC) family of proteins. 7 It was initially identified as a transcriptional repressor and along with TIF1a has been shown to be fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. 8, 9 The zebra fish TIF1g ortholog, mon, is required for differentiation of erythroid progenitor cells and posterior mesenchymal cells. 10 Recent work suggests that the TGF-b-dependent differentiation of hematopoietic, mesenchymal and epithelial cells is dependent upon the ability of TIF1g to compete with SMAD4 for binding to activated SMAD2/SMAD3 transcription factor complexes. 11 Other workers suggest that TIF1g serves as a SMAD4 monoubiquitin ligase and inhibits TGF-b signaling pathways by dissociating SMAD2/3-SMAD4 complexes. 12, 13 To explore further the complexity of APC/C function, we undertook mass spectrometric analyses to identify novel APC/Cbinding partners. Here, we detail the characterization of TIF1g as an APC/C-interacting protein that affects APC/C activity in mitosis. We show that TIF1g interacts specifically with APC3 and Cdc20, and regulates cell cycle progression through mitosis; TIF1g knockdown reduces APC/C-Cdc20 ligase activity, stabilizes APC/C substrate levels and leads to an accumulation of cells in metaphase. Consistent with these observations, the time taken for cells to pass from nuclear envelope breakdown (NEBD) to anaphase increases significantly following TIF1g knockdown. Indeed, a significant proportion of TIF1g knockdown cells fail to undergo metaphase-to-anaphase transition. TIF1g knockdown cells are also characterized by the inappropriate expression of APC/C substrate cyclin A at metaphase and metaphases with misaligned chromosomes. Consistent with a role for TIF1g in mitosis, a small interfering RNA (siRNA)-resistant TIF1g relieves the mitotic block imposed by TIF1g knockdown and allows for cell cycle progression. The mitotic phenotype exhibited by TIF1g knockdown cells is also relieved by inactivation of the SAC, suggesting that TIF1g activity in mitosis is monitored by the SAC, such that TIF1g inactivation results in SAC activation. Taken together, this work defines a new role for TIF1g in regulating progression through mitosis.
RESULTS
TIF1g associates with the APC/C and Cdc20 but it is not a substrate for APC/C-directed ubiquitylation To identify novel APC/C-interacting proteins, we performed immunoprecipitation from an asynchronous population of HeLa cells, with anti-APC7 antibodies. We subsequently isolated protein bands following SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed tryptic peptides using a Thermo Fisher Scientific (Hemel Hempstead, UK) LCQ DECA XP Plus ion trap as described previously. 14 In addition to identifying peptides specific for APC7, a number of APC/C subunits and the APC/C E2, UbcH10, we also isolated peptides specific for TIF1g (amino-acid residues 394-407, KLLQQQNDITGLSR and 482-504, PAPGYTPNVVVGQVPP GTNHISK). To verify these findings we made an antibody that was specific for TIF1g (Figures 1a and 3a) and then assessed the ability of the APC/C holoenzyme to interact with TIF1g. Reciprocal immunoprecipitation: western blot analyses revealed that TIF1g co-immunopreciptated with a number of distinct APC/C subunits and that APC/C components co-immunoprecipitated with TIF1g (Figures 1a and b) . These analyses revealed that TIF1g associated preferentially with a higher molecular weight form of APC7, although it also bound the major APC7 form as well ( Figure 1b ). Further analyses revealed that TIF1g associated specifically with the APC/C activator Cdc20, but did not associate with Cdh1 (Figures 1c and d) . To assess the stoichometry of TIF1g association with the APC/C, we next determined the ability of TIF1g, relative to APC/C activators, Cdc20 and Cdh1, to bind to APC/C subunits. This experiment revealed that TIF1g associated with a smaller pool of APC3, relative to Cdc20 and Cdh1, and a smaller pool of APC5, relative to Cdc20 (Figure 1d ). These analyses also revealed that TIF1g associated more efficiently with the higher molecular weight form of APC7 than Cdc20 or Cdh1, although TIF1g, Cdc20 and Cdh1, all bound the major form of APC7 with equal avidity (Figure 1d ). Glutathione-S-transferase (GST) pull-downs revealed that TIF1g associated preferentially with APC3 and Cdc20 ( Figure 1e ). As TIF1g binds the APC/C, and possesses three potential RxxL destruction box motifs within its primary sequence (residues 440-443, 968-971 and 1114-1117), we next investigated whether TIF1g is a target for APC/C ubiquitin ligase activity. First, we performed in vitro ubiquitin ligase assays with anti-APC3 immunoprecipitates using [ 35 S]-labeled TIF1g, or [ 35 S]-labeled cyclin B1 as substrates. Consistent with previous findings cyclin B1 was efficiently polyubiquitylated in an APC/C-dependent manner, whereas TIF1g was not a target for APC/C-directed ubiquitin ligase activity in this assay ( Figure 1f ). Next, we assessed TIF1g protein levels in vivo, following the release of cells from a nocodazole-induced mitotic block. In accordance with the in vitro APC/C ligase assays, cyclin B1 levels were reduced significantly following the passage of cells through mitosis and into the successive G1 phase, whereas levels of the TIF1g protein were not altered following the release of the cells from the mitotic block ( Figure 1g ). However, it appeared that TIF1g was subject to posttranslational modification in nocodazole-treated cells, as gauged by reduced mobility upon SDS-PAGE ( Figure 1g ). To confirm our findings that TIF1g is not targeted for degradation by the APC/C, we next assessed TIF1g protein levels following the exogenous expression of Myc-tagged Cdc20 and Cdh1 (Figure 1h ). TIF1g levels remained unaffected following the expression of Cdc20 or Cdh1, whereas the levels of APC/C-Cdc20 substrate, NEK2A, were reduced following Myc-tagged Cdc20 expression, and levels of APC/C-Cdh1 substrate, PLK1, were reduced following the expression of Myc-tagged Cdh1 (Figure 1h ). In agreement with these observations, TIF1g protein levels were not altered following the ablation of Cdc20, or Cdh1, expression by RNAi ( Figure 3a ). To substantiate these findings, we determined whether knockdown of the APC/C inhibitor, Emi1, 15, 16 or knockdown of Cdh1, affected TIF1g protein levels following release from a mitotic block ( Figure 1i ). This experiment revealed that although Emi1 knockdown, relative to non-silencing controls, prevented the reaccumulation of cyclin A 18 h after nocodazole release, it did not affect appreciably the levels of TIF1g (lanes 4 and 8; Figure 1i ). Similarly, Cdh1 knockdown allowed the early accumulation of cyclin B1 at 18 h after nocodazole release, but did not enhance TIF1g levels (lanes 4 and 12; Figure 1i ). Taken together these data indicate that TIF1g associates preferentially with APC/C-Cdc20, but that TIF1g is not a substrate for APC/C-Cdc20-, or APC/C-Cdh1-, directed ubiquitylation.
TIF1g associates preferentially with the APC/C in mitosis and S phase As Cdc20 binding to the APC/C is cell cycle-regulated and TIF1g binds preferentially to APC/C-Cdc20, we thought it appropriate to examine the ability of TIF1g to bind to the APC/C during each stage of the cell cycle. To do this, we collected highly enriched populations of mitotic, G1, S and G2 HeLa cells and subjected them to immunoprecipitation with anti-APC7 antibodies, followed by western blotting for TIF1g. Consistent with the ability of TIF1g to bind APC/C-Cdc20, we determined that TIF1g had a greater capacity to bind the APC/C in mitosis than in G1 or G2 phases, despite TIF1g levels not changing appreciably during the cell cycle (Figure 2a ). TIF1g also had a greater ability to bind the APC/C in S phase, relative to its ability to bind the APC/C in G1 and G2 phases (Figure 2a ). Cell cycle status was verified by blotting for cell cycle-regulated proteins (Figure 2a ). Given that TIF1g associates preferentially with Cdc20, and not Cdh1 (Figure 1 ), and that TIF1g interaction with the APC/C is cell cycle dependent (Figure 2a ), we hypothesized that TIF1g might associate with the APC/C only in discrete phases of mitosis. To investigate this possibility, we immunoprecipitated APC7 complexes from nocodazole-treated cells and those cells released back into the cell cycle following nocodazole withdrawal, and subsequently performed western blots for TIF1g. Interestingly, the ability of TIF1g to bind the APC/C was maximal in SAC-activated cells, but was reduced appreciably once the SAC was satisfied and cells were allowed to progress through mitosis ( Figure 2b ). To establish whether TIF1g also bound Cdc20 in a cell cycle-dependent manner, we next immunoprecipitated Cdc20 and TIF1g from mitotic, G1, S and G2 populations of HeLa cells and performed the corresponding TIF1g and Cdc20 western blots ( Figure 2c ). These analyses revealed that TIF1g associated with Cdc20 exclusively in mitosis, suggesting a role for TIF1g-APC/C-Cdc20 complexes, specifically in mitosis ( Figure 2c ). Given these findings and those that suggest that TIF1g associates with APC3 and Cdc20 independently ( Figure 1d ), we next determined whether Cdc20, or Cdh1, knockdown affected the ability of TIF1g to interact with the APC/C holoenzyme ( Figure 2d ). Significantly, the ability of TIF1g to associate with the APC/C was not affected by Cdc20, or Cdh1 knockdown, suggesting that TIF1g might also affect APC/C function, independent of its association with Cdc20. These data suggest that TIF1g associates directly with the APC/C. Whether TIF1g associates with Cdc20 directly, in vivo, remains unknown.
TIF1g knockdown stabilizes the levels of APC/C substrates and blocks cells in mitosis
To address the functional significance of the TIF1g-APC/C interaction, we first investigated whether TIF1g expression affects the levels of known APC/C substrates. We therefore ablated TIF1g expression in HeLa cells using two different siRNAs and then determined the protein levels of different APC/C substrates by western blotting. As positive controls we also determined the effects of Cdc20 and Cdh1 knockdown upon APC/C substrate levels. These analyses revealed that the knockdown of TIF1g, Cdc20 and Cdh1 was highly efficient; knockdown was essentially complete after 24 h and protein levels remained low for the duration of the experiment (Figure 3a) . Consistent with the notion that TIF1g might regulate APC/C ligase activity, the protein levels of APC/C substrates cyclin A, cyclin B1, Aurora A, PLK1 and Cdc20 were all elevated in cells treated with siRNAs against TIF1g, relative to non-silencing controls (Figure 3a ). Cdc20 Figure 1 . TIF1g associates with the APC/C but is not a substrate for APC/C ligase activity. (a-d) APC/C components, Cdc20, Cdh1 and TIF1g, were immunoprecipitated from asynchronous whole-cell HeLa extracts, separated by SDS-PAGE, and western blotted for coprecipitating proteins. APC7 (s), short exposure; APC7 (l), long exposure. (e) TIF1g binds to APC3 and Cdc20 in vitro. GST and GST-APC2, APC3, APC5, APC6, APC7 and Cdc20 fusion proteins were incubated with L-a-[ 35 S]-methionine-labeled TIF1g. GST fusion, and binding proteins were purified upon glutathione-agarose beads and separated by SDS-PAGE. The binding of TIF1g to GST proteins was assessed following autoradiography of the dried gel. *Indicates full-length GST fusion protein; upper band in GST lane is GST dimer. (f ) APC/C complexes were immunoprecipitaed from asynchronous whole-cell HeLa extracts using an anti-APC3 monoclonal antibody. APC/C immune complexes were assayed for E3 ligase activity in the presence of L-a-[ 35 S]-methionine-labeled cyclin B1 or TIF1g. After 1 h incubation samples were separated by SDS-PAGE. Polyubiquitylation of cyclin B1 and TIF1g was assessed following autoradiography of the dried gel. (g) TIF1g is post-translationally modified in response to nocodazole treatment but it is not degraded following nocodazole release (noc rel). HeLa cells were treated with 200 ng/ml nocodazole for 20 h. Mitotic cells were then isolated by shake-off and either harvested, or released back into cycle following the removal of nocodazole and then harvested at later times. Proteins were separated by SDS-PAGE and then western blotted for TIF1g, cyclin B1 and b-actin. Lane 1: asynchronous cells (A); lane 2: mitotic shake-off following nocodazole treatment (0); lanes 3-5: 1, 2 and 4 h post nocodazole release. (h) TIF1g is not targeted for degradation by Cdc20 or Cdh1. HeLa cells were transfected with mammalian expression plasmids expressing either Myc-tag alone (Myc-EV), Myc-tagged Cdc20 or Myc-tagged Cdh1. Samples were harvested 24 h post transfection and subjected to SDS-PAGE and western blotting. (i) Emi1 knockdown does not promote TIF1g degradation. HeLa cells were treated with non-silencing siRNA, Emi1 and Cdh1 siRNAs. Forty-eight hours post-knockdown cells were treated with 200 ng/ml nocodazole for 20 h. Mitotic shake-off cells were then released from the nocodazole block (noc rel) and harvested at the times indicated and subject to SDS-PAGE and western blotting.
affected the protein levels of APC/C substrates as expected ( Figure 3a ). Given these findings, we next investigated whether TIF1g knockdown affected cell cycle distribution. We therefore treated asynchronous HeLa cells with the appropriate siRNAs and then determined cell cycle status 72 h post treatment ( Figure 3b ). Propidium iodide staining indicated that there were a greater proportion of TIF1g knockdown cells in G2/M, relative to nonsilencing controls (Figure 3b ). In accordance with the established role of the APC/C in mitosis and the affect of TIF1g knockdown on the levels of APC/C substrates, phospho-serine 10 histone H3 staining revealed that there was also a dramatic increase in the mitotic index following TIF1g knockdown, relative to non-silencing controls ( Figure 3b ). Treatment of cells with the TIF1g-1i siRNA caused a greater than 14-fold increase in the mitotic index relative to non-silencing siRNA, whereas TIF1g-2i siRNA increased the number of cells in mitosis approximately six-fold ( Figure 3b ). As TIF1g also regulates transcription, we next investigated whether TIF1g knockdown affected the protein levels of APC/C subunits ( Figure 3c ). Significantly, ablation of TIF1g expression by RNAi did not downregulate the protein levels of APC/C subunits (Figure 3c ), suggesting that TIF1g transcriptional activity does not account for its effects upon the APC/C. Taken together, these data are important in establishing a potential role for TIF1g in modulating APC/C activity and regulating cell cycle progression.
TIF1g knockdown prolongs the time taken to progress through mitosis Given these findings we next addressed whether TIF1g regulates progression through mitosis. We therefore performed live-cell differential interference contrast, and immunofluorescent, video microscopy with HeLa cells expressing EGFP-labeled a-tubulin and mCherry-labeled histone H2B and calculated the time taken for cells, treated with non-silencing siRNA or siRNAs targeted against TIF1g, to progress from the beginning of NEBD to anaphase ( Figure 4 ). Consistent with a role for TIF1g in mitosis, cells treated with non-silencing siRNA took on an average 105.2 min to pass from NEBD to anaphase, whereas cells treated with siRNAs targeted against TIF1g, TIF1g-1i and TIF1g-2i, took 199.04 min and 142.2 min, respectively (Figures 4a-c). Interestingly, a large proportion of the cells treated with siRNAs targeted against TIF1g appeared to have prolonged metaphases that were characterized by a failure to undergo metaphase-to-anaphase transition ( Figure 4e ). Indeed, image analysis revealed that those TIF1g knockdown cells that failed to undergo metaphase-to-anaphase transition were characterized at late times by plasma membrane blebbing, compacted chromatin and aberrant mitotic spindle formation. Close inspection of the data revealed that only three cells of fifty analyzed took over 300 min to pass from NEBD to anaphase following treatment with non-silencing siRNA (Figure 4a ), whereas there was a threefold increase in the number of cells taking over 300 min to pass from NEBD to anaphase Figure 2 . TIF1g association with the APC/C and Cdc20 is cell cycle dependent. (a) TIF1g binds the APC/C preferentially in mitosis and S phase. HeLa whole-cell extracts were prepared from G1, S, G2 and M phase enriched cell populations. APC7 was then immunoprecipitated from each fraction, isolated upon Protein G Sepharose and the relative amount of TIF1g associated with APC7 immune complexes was determined by western blot. Cell cycle status was verified by western blotting for cyclins A, B, phospho Ser10-Histone H3 (pH3) and a-tubulin. (b) The ability of TIF1g to bind the APC/C decreases once the SAC is satisfied and cells progress through mitosis. HeLa cells were treated with 200 ng/ml nocodazole for 20 h. Mitotic cells were then isolated by shake-off and either harvested or released back into cycle following the removal of nocodazole and then harvested at later times. APC7 was then immunoprecipitated from cell lystaes, isolated upon Protein G Sepharose and TIF1g binding to the APC/C was assessed by western blot. Levels of BubR1, cyclin B1, APC4, APC7, TIF1g and a-tubulin were also assessed by western blot. (c) TIF1g binds Cdc20 preferentially in mitosis. HeLa whole-cell extracts were prepared from G1, S, G2 and M phase enriched cell populations. Cdc20 and TIF1g was then immunoprecipitated from each fraction, isolated upon Protein G Sepharose, and the relative amount of TIF1g associated with Cdc20 was determined by western blot. (d) Cdc20 knockdown does not affect APC/C association with TIF1g HeLa cells were treated with non-silencing siRNA, Cdc20, and Cdh1 siRNAs. Forty-eight hours post knockdown cells were harvested and subjected to immunoprecipitation with anti-TIF1g antibodies. Following SDS-PAGE, TIF1g association with the APC/C was assessed by western blotting. (Figure 4 ). Taken together these data are supportive of the notion that TIF1g functions to regulate progression through mitosis.
TIF1g knockdown leads to an accumulation of cells in metaphase
To substantiate these findings further, we next investigated whether TIF1g knockdown affects mitotic distribution. To do this we treated asynchronous HeLa cells with either non-silencing siRNAs or siRNAs targeted against TIF1g and determined the number of cells in prophase, prometaphase, metaphase, anaphase and telophase by immunofluorescent microscopy. Consistent with the observation that TIF1g knockdown affects progression from NEBD to anaphase, it was notable that TIF1g knockdown with either TIF1g siRNA caused a significant increase in the number of metaphase cells and a corresponding, significant decrease in the number of anaphase and telophase cells ( Figure 5a ). These data support the idea that TIF1g regulates metaphase-to-anaphase transition.
Loss of TIF1g expression results in SAC activation
It was evident while analyzing the effect of TIF1g knockdown upon mitotic distribution that although all TIF1g knockdown cells in metaphase had a characteristic bipolar spindle, the majority of these cells (490%) had misaligned chromosomes. We reasoned therefore that TIF1g depletion might result in the activation of the SAC. To address this possibility, we treated HeLa cells with either non-silencing siRNAs or siRNAs targeted against TIF1g, and assessed Bub1 association with kinetochores. Consistent with the idea that the SAC is activated following TIF1g knockdown, microscopic studies revealed that Bub1 was associated with the kinetochores of misaligned chromosomes at metaphase in TIF1g knockdown cells ( Figure 5b ). Furthermore, western blotting revealed that TIF1g knockdown promoted the upregulation and phosphorylation of SAC regulators Bub1 and BubR1 (Figure 5c ). To substantiate these findings, we next attempted to override the SAC phenotype displayed by TIF1g knockdown cells, by coordinately ablating the expression of both TIF1g and BubR1 (Figure 5d ). Consistent with the hypothesis that TIF1g knockdown activates the SAC, we determined that cells depleted of TIF1g alone had elevated levels of cyclin B1, phospho-serine 10 histone H3 and phosphorylated BubR1 (Figure 5d ), whereas cells depleted of both TIF1g and BubR1 had substantially reduced levels of cyclin B1 and phospho-serine 10 histone H3, relative to cells treated with non-silencing siRNA or TIF1g siRNA (Figure 5d ). These results indicate that knockdown of BubR1 relieves SAC activation induced by TIF1g knockdown, and allows for metaphase-to-anaphase transition and mitotic exit. Taken together these data indicate that the SAC is activated following TIF1g knockdown and that TIF1g regulates APC/C function before anaphase.
TIF1g is also associated with the APC/C-MCC in SAC-activated cells To examine the relationship between TIF1g and the SAC in more detail, we investigated the ability of TIF1g to associate with BubR1, the APC/C and Cdc20 upon SAC activation. Initially, we determined the relative abilities of TIF1g and the APC/C to associate with Cdc20 and BubR1 in asynchronously growing HeLa cells, and HeLa cells collected by mitotic shake-off where the SAC was activated by nocodazole treatment (Figure 5e ). In line with our studies examining TIF1g association with the APC/C, both the APC/C and TIF1g had a greater propensity to bind to Cdc20 and (a) Mitotic APC/C substrates are stabilized following TIF1g knockdown. HeLa cells were treated with either non-silencing siRNA, or siRNAs specific for TIF1g. Cell lysates were prepared at the times indicated and levels of APC/C substrates determined by western blotting. TIF1g levels were determined to monitor knockdown efficiency and a-actin levels were determined as a loading control. (b) TIF1g knockdown increases the mitotic index. HeLa cells were treated with either non-silencing siRNA, or siRNAs specific for TIF1g. Cells were fixed in 70% (v/v) ice-cold ethanol 72 h post transfection and subsequently subjected to fluorescence-activated cell sorting analysis, following costaining with propidium iodide, to gauge cell cycle distribution, and an anti-phospho Ser10-Histone H3 antibody to gauge the numbers of cells specifically in mitosis. ***Po0.001; data taken from three independent experiments. Error bars represent standard deviation. (c) TIF1g knockdown does not affect APC/C subunit expression. HeLa cells were treated with either nonsilencing siRNA, or siRNAs specific for TIF1g, Cdc20 and Cdh1. Fortyeight hours post-knockdown cells were harvested and subject to SDS-PAGE and western blotting. (Figure 5e ). Consistent with these findings, the APC/C also had a greater propensity to bind BubR1 when TIF1g levels were depleted by siRNA ( Figure 5e ). There was, however, only a modest increase in TIF1g-APC7 association following SAC activation, suggesting that TIF1g association with the APC/C holoenzyme is largely SAC independent ( Figure 5e ). As APC15 has recently been implicated in controlling the SAC by regulating the APC/C-dependent turnover of mitotic checkpoint complex (MCC) components, 17 we investigated whether TIF1g was also involved in regulating MCC turnover. To do this we activated the SAC in HeLa cells and monitored MCC attachment to the APC/C in cells where TIF1g or APC15 had been depleted by siRNA. Consistent with its known function, APC15 depletion stabilized MCC association with the APC/C, whereas TIF1g did not (Figure 5f ). These data indicate that although TIF1g is associated with the APC/C-MCC in SAC-activated cells, it is not required to inactivate the SAC.
Role for TIF1g in APC/C-mediated degradation of cyclin A and cyclin B1 in mitosis
To determine a direct role for TIF1g in the APC/C-mediated degradation of APC/C substrates in mitosis, we next performed in vitro APC/C ubiquitin ligase assays upon anti-APC3 immunoprecipitates from HeLa cells treated with either non-silencing siRNA, or siRNA against TIF1g. These experiments revealed that TIF1g knockdown, relative to non-silencing controls, reduced substantially the ability of the APC/C to polyubiquitylate [ 35 S]labeled cyclin A by about 80% (Figure 6a ). As cyclin A degradation is typically SAC independent, 18, 19 these data are supportive of a model whereby TIF1g modulates APC/C-Cdc20 activity directly to regulate the polyubiquitylation of cyclin A. To determine whether the impairment of APC/C ubiquitin ligase activity in TIF1g knockdown cells also extends to SAC-dependent substrates, we assessed the ability of the APC/C immunoprecipitated from HeLa cells, treated with either non-silencing siRNA, or siRNA against TIF1g, to ubiquitylate cyclin B1 (Figure 6a ). Consistent with a more general role for TIF1g in the regulation of APC/C activity, TIF1g knockdown, relative to non-silencing controls, reduced the ability of the APC/C to polyubiquitylate [ 35 S]-labeled cyclin B1 by B60% (Figure 6a ).
As the APC/C and Cdc20 cooperate in binding substrates, 20,21 and data presented here has determined that TIF1g associates with APC/C-Cdc20, and affects APC/C-Cdc20 activity in mitosis, we next investigated whether TIF1g was also able to associate with the APC/C substrates, cyclin A and cyclin B1. Consistent with the Figure 4 . TIF1g knockdown delays progression through mitosis from NEBD to anaphase. HeLa cells expressing Histone H2B mCherry and a-tubulin-EGFP were treated with either an siRNA specific for luciferase or siRNAs specific for TIF1g. 48 h post-knockdown cells were subjected to a thymidine block for 16 h, whereupon cells were released back into cycle and video imaging began 9 h later. Video images representative of treatments with (a) luciferase siRNA (b) TIF1g-1i siRNA and (c) TIF1g-2i siRNA are presented. Corresponding bar charts illustrating the time taken for cells to progress from NEBD to anaphase are also presented.^Represents cells that failed to exit mitosis during filming. *Represents cells that failed to undergo successful metaphase-to-anaphase transition during filming (depicted in Figure 4e ). Differential interference contrast and immunofluorescent imaging revealed that those cells that failed to undergo metaphase-to-anaphase transition were characterized at late times by plasma membrane blebbing, compacted chromatin and aberrant mitotic spindle formation. Video imaging was therefore terminated at this time and the time taken from NEBD to this point was recorded. The mean values calculated for time taken from NEBD to anaphase are therefore underestimated for those cells that failed to undergo metaphase-to-anaphase transition. (d) Western blot for TIF1g and a-tubulin in cells treated with luciferase siRNA, TIF1g-1i or TIF1g-2i siRNAs.
idea that TIF1g modulates APC/C activity during mitosis, TIF1g was able to bind cyclin A in vivo (Figure 6b) ; it was not, however, able to bind cyclin B1 (Figure 6b ). Consistent with this finding [ 35 S]labeled TIF1g also associated specifically with GST-cyclin A in vitro (Figure 6b ). Taken together these data support the notion that TIF1g promotes the APC/C-Cdc20-dependent degradation of cyclin A in mitosis potentially through interaction with the APC/C holoenzyme, Cdc20, and cyclin A itself. These data also suggest that TIF1g can affect APC/C E3 ligase activity directed toward cyclin B1, independently of binding to cyclin B1. As the APC/Cmediated degradation of cyclin A normally begins at the onset of NEBD in mitosis, 22 we next investigated whether cyclin A expression was elevated in metaphase cells where TIF1g expression had been ablated by RNAi. As before, TIF1g knockdown resulted in metaphase cells with misaligned chromosomes (Figure 6c ). Consistent with the western blot data (Figure 3a) , confocal microscopy revealed that cyclin A levels were higher in TIF1g knockdown cells at metaphase, relative to cells treated with non-silencing siRNA (Figure 6c ); TIF1g cells expressing elevated levels of cyclin A at metaphase had characteristic misaligned chromosomes (Figure 6c ). delay in a SAC-independent manner, 22 we wanted to discern whether TIF1g knockdown affected cell cycle progression through mitosis independently of the SAC through the modulation of endogenous cyclin A levels or, alternatively, affected mitotic progression in a SAC-dependent manner. To do this, we investigated by differential interference contrast, immunofluorescent and video microscopy the effect of dual TIF1g and BubR1 knockdown in HeLa cells upon the time taken for cells to progress from NEBD to anaphase (Figure 7 ). As we previously demonstrated, TIF1g knockdown alone resulted in a significant delay in the ability of cells to progress through mitosis and undergo metaphase-to-anaphase transition (Figures 7a, b and f) , whereas BubR1 knockdown alone resulted in more rapid progress from NEBD to anaphase, relative to control cells, presumably as the SAC had been inactivated (Figures 7a and c) . Cells that were depleted of both TIF1g and BubR1 progressed through mitosis with similar kinetics to those cells that had been treated with BubR1 siRNA alone (Figures 7c and d) . Taken together these data suggest that the ability of TIF1g to affect cell cycle progression through mitosis is mediated exclusively through the SAC.
TIF1g mitotic effects are dependent upon the SAC As overexpression of exogenous cyclin A has previously been reported to result in chromosome misalignment and anaphase
Cellular expression of a siRNA-resistant TIF1g facilitates mitotic progression and mitotic exit As TIF1g knockdown leads to the accumulation of APC/C substrates and SAC activation, we reasoned that expression of a siRNA-resistant TIF1g might restore APC/C activity against mitotic substrates and allow cells to progress through, and exit mitosis. To investigate this possibility, we first ablated TIF1g expression by siRNA and, 48 h later, transfected knockdown cells with a siRNAresistant FLAG-tagged TIF1g species. We harvested cells 24 h post transfection and performed western blot analyses to determine the consequences of TIF1g expression on APC/C function (Figure 7g ). Importantly, these analyses revealed that expression of the siRNA-resistant FLAG-tagged TIF1g species reversed TIF1g knockdown effects and led to a significant reduction in the levels of the APC/C substrate, cyclin A, and the mitotic indicator, phospho-serine 10 histone H3 (Figure 7g ). Taken together these data support the notion that TIF1g regulates APC/C activity directly and allows for the temporally coordinated APC/Cdependent progression of cells through mitosis.
DISCUSSION
In this report we have identified TIF1g as an APC3 and Cdc20 binding protein that associates specifically in vivo with the APC/C holoenzyme, APC/C-Cdc20 and APC/C-MCC complexes and promotes mitotic progression (Figures 1-7) . In this regard TIF1g associated with a number of APC/C subunits in vivo (Figure 1) . Interestingly, TIF1g associated with two forms of APC7, a major 66-kDa species and a minor 75-kDa species; TIF1g associated preferentially with the minor species (Figures 1b and d) . It is not clear at present whether this minor species of APC7 represents an APC7 isoform, or whether it is a post-translationally modified form of the major APC7 species. It will be important to characterize the minor form of APC7, as it might give new insight into APC/C function. We also presented considerable evidence to indicate that TIF1g is not a substrate for APC/C-dependent ubiquitylation (Figures 1 and 3c ) and that it associated preferentially with Cdc20 and not Cdh1 (Figure 1 ). Perhaps surprisingly, TIF1g associated with the APC/C in S phase, as well G2 and mitosis (Figure 2 ). Previous reports have suggested that Emi1 acts as a pseudosubstrate inhibitor of the APC/C to prevent premature APC/C activation; 15, 16 it will be of interest to determine whether TIF1g Figure 6 . Cyclin A is stabilized in mitotic TIF1g knockdown cells and is degraded upon expression of an siRNA-resistant TIF1g species. (a) APC/C ligase activity directed toward cyclin A and cyclin B1 is reduced following TIF1g knockdown. HeLa cells were treated with either non-silencing siRNA or siRNAs specific for TIF1g. The APC/C holoenzyme was immunoprecipitated from cell lysates 72 h post treatment using an antibody to APC3. APC/C activity was then assayed by incubating anti-APC3 immunoprecipitates with L-a-[ 35 S]-methionine-labeled cyclin A or cyclin B1. After 1 h incubation samples were separated by SDS-PAGE and polyubiquitylation of cyclin A and cyclin B1 was assessed following autoradiography of the dried gel. (b) TIF1g associates with cyclin A but not cyclin B1. HeLa cells were subject to immunoprecipitation with TIF1g, and western blotted for cyclin A or cyclin B1; GST and GST-cyclin A were incubated with L-a-[ 35 S]-methionine-labeled TIF1g. GST fusion, and binding proteins were purified upon glutathione-agarose beads and separated by SDS-PAGE. The binding of TIF1g to GST-cyclin A was assessed following autoradiography of the dried gel. *Indicates full-length GST fusion protein; upper band in GST lane is GST dimer (c), cyclin A is inappropriately present at metaphase in TIF1g knockdown cells. HeLa cells were treated with either non-silencing siRNA or siRNAs specific for TIF1g, and seeded onto glass slides. Seventy-two hours post transfection cells were fixed and permeabilized and then costained with either a-tubulin, TIF1g and DAPI (i) or cyclin A and DAPI (ii). Arrowheads indicate misaligned chromosomes in TIF1g-knockdown cells.
functions in a similar manner to regulate APC/C activity during S phase. Our data also revealed that TIF1g associated with Cdc20 preferentially in mitosis ( Figure 2 ) and that Cdc20 knockdown did not appreciably affect TIF1g association with the APC/C (Figure 2 ). It will be of interest in the future, therefore, to dissect the relative contributions of TIF1g-APC/C-and TIF1g-Cdc20 interactions in controlling mitotic progression.
It is now well established that APC/C-Cdc20 promotes the degradation of early mitotic substrates such as Nek2A and cyclin A 22,23 and initiates metaphase-to-anaphase transition by promoting the polybiquitylation and proteasomal-mediated degradation of the separase inhibitor, securin. 1, 2 We determined that TIF1g knockdown reduces APC/C ligase activity, stabilizes APC/C substrates and increases the number of cells in metaphase, relative to control-treated cells (Figures 3, 5 and 6 ). Our studies also revealed that TIF1g knockdown prolonged the time taken for cells to pass from NEBD to anaphase and that a significant proportion of TIF1g knockdown cells failed to undergo metaphase-to-anaphase transition (Figures 4 and 5a) . Consistent with these findings, we established that TIF1g knockdown promotes SAC activation ( Figure 5 ). The notion that TIF1g inactivation promotes SAC activation is supported by the observation that knockdown of the SAC component, BubR1, can overcome SAC activation imposed by TIF1g knockdown (Figures 5d and 7) . However, unlike APC15, which regulates SAC by coordinating MCC dissociation from the APC/C, TIF1g does not play a role in regulating SAC inactivation (Figure 5f) . A direct role for TIF1g in mitotic progression was given credence by the observation that siRNA-resistant TIF1g relieves SAC activation, promotes cyclin A degradation, and facilitates cell cycle progression through mitosis (Figure 7g ). Collectively, these data indicate that, not only does TIF1g modulate APC/C-Cdc20 activity and the progression of cells through mitosis, it also associates with the APC/C-MCC.
The APC/C-Cdc20-mediated degradation of early mitotic substrates such as cyclin A occurs despite SAC activation. 19, 24 It has been suggested that cyclin A outcompetes SAC proteins for binding to Cdc20 and that cyclin A-Cdc20 complexes are subsequently recruited to the APC/C by the cyclin-dependent kinase cofactor, Cks. 19, 24 As TIF1g binds specifically to APC/C-Cdc20 complexes and cyclin A in vivo, and has the capability to bind to Cdc20, APC3 and cyclin A independently in vitro ( Figures  1 and 6b) , it is possible that TIF1g cooperates with Cdc20 and Cks in the binding and recruitment of cyclin A to the APC/C. Given that TIF1g knockdown also affects the ability of the APC/C to polyubiquitylate cyclin A (Figure 6a ), TIF1g might facilitate the degradation of cyclin A by modulating APC/C-Cdc20 ligase activity directly. The notion that TIF1g functions directly to regulate APC/C activity is supported by the observations that the APC/C-Cdc20dependent degradation of cyclin A is SAC independent, and that significantly more APC/C ligase activity against cyclin A can be Figure 7 . Inactivation of the SAC allows TIF1g knockdown cells to pass through mitosis from NEBD to anaphase. HeLa cells expressing Histone H2B mCherry and a-tubulin-EGFP were treated with either an siRNA specific for luciferase (a) or siRNAs specific for TIF1g (b), BubR1 (c) or TIF1g and BubR1 (d) 48 h post-knockdown cells were subjected to a thymidine block for 16 h, whereupon cells were released back into cycle and video imaging began 9 h later. Bar charts depicting time taken to pass from NEBD to anaphase are presented. *Represents cells that failed to undergo successful metaphase-to-anaphase transition during filming (depicted graphically in Figure 7f ). (e) Western blots for TIF1g, BubR1 and a-tubulin in cells treated with luciferase, TIF1g, BubR1 or TIF1g and BubR1 siRNAs. (g) Expression of a siRNA-resisitant TIF1g species allows for cyclin A degradation and mitotic progression. HeLa cells were treated with either non-silencing siRNA or siRNAs specific for TIF1g for 48 h. Cells were then transfected with vector alone or a construct expressing FLAG-TIF1g and cultured for a further 24 h. Cell lysates were prepared and the levels of FLAG-TIF1g, endogenous TIF1g, cyclin A, phospho Ser10-histone H3 (pH3) and b-actin were all determined by western blot.
Individual cells n=43
Time from NEBD to anaphase (min) Time from NEBD to anaphase (min)
Time from NEBD to anaphase (min)
Individual cells n=38
Individual cells n=36 4  7  10  13  16  19  22  25  28  31  34  5  9  13  17  21  25  29  33  37 TIF1g in mitosis GG Sedgwick et al immunoprecipiated from asynchronous cells relative to TIF1g knockdown cells, even though there are between 5-and 10-fold more cells in mitosis following TIF1g knockdown (Figures 5a  and 6a) . A more general role for TIF1g in modulating APC/C ubiquitin ligase activity is given credence by the observation that TIF1g knockdown also affects the ability of the APC/C to polyubiquitylate cyclin B1 (Figure 6a ). It is possible therefore that TIF1g might function more generally to affect APC/C ligase activity directed toward its substrates.
Pertinently, it is has previously been demonstrated that cyclin A is targeted for degradation by APC/C-Cdc20 at the commencement of NEBD, and that cyclin A degradation is required for proper chromosome alignment at metaphase; cyclin A overexpression delays chromosome alignment and anaphase onset. 22 As TIF1g knockdown leads to an increase in metaphase cells, a concomitant reduction in the number of anaphase and telophase cells, and the stabilization of cyclin A at metaphase (Figures 3 and 6b ), it could be reasoned that increased cyclin A expression in TIF1g knockdown cells is responsible, at least in part, for the mitotic phenotype observed in these cells (Figures 3 and 4 ). It has been suggested that cyclin A overexpression delays metaphase-toanaphase transition independently of SAC as MAD2 does not appear to associate with kinetochores in this instance, although whether it promotes BubR1 association with the APC/C, akin to TIF1g knockdown, has not been investigated. 22 As SAC inactivation relieves completely the mitotic phenotype imposed by TIF1g knockdown (Figures 5d and 7) , our data indicate that SAC inactivation overcomes any cell cycle restrictions imposed by the inappropriate presence of endogenous cyclin A at metaphase in TIF1g knockdown cells, such that chromosome misalignment at metaphase in TIF1g knockdown cells is subject to control by the SAC (Figure 7) . It is perhaps not surprising that the TIF1g knockdown phenotype shares only some characteristics of the cyclin A overexpression phenotype, as it might be expected that TIF1g knockdown reduces APC/C ligase activity directed against other substrates that modulate progression through mitosis (Figures 3a and 6a ). In this regard, it is possible that the reduction of APC/C activity per se in TIF1g knockdown cells leads to the accumulation of APC/C substrates that activate and/or sustain the SAC. It is also possible that TIF1g has other activities in mitosis, unrelated to its ability to affect APC/C ligase activity that regulates chromosome attachment. For instance, TIF1g might ubiquitylate components of the kinetochore or MCC to coordinate chromosome attachment. TIF1g association with chromatin might also promote mitotic progression. These possibilities, however, await investigation.
Indeed, it has recently been reported that the cell permeable, prodrug form of the small molecule inhibitor of the APC/C, tosyl-Larginine methyl ester (TAME), proTAME, induces a SAC-dependent metaphase arrest in the absence of spindle damage. 25 As the proteasome inhibitor, MG132, also promotes a SAC-dependent mitotic arrest, the authors of this article proposed that APC/Cdependent proteolysis was required to inactivate the SAC, and that APC/C inhibition activated the SAC. Interestingly, some laboratories have proposed that the APC/C-mediated ubiquitylation, but not degradation, of Cdc20 releases the APC/C from SAC inhibition, 26, 27 although we and others suggest that APC/Cmediated ubiquitylation and degradation of Cdc20 sustains the SAC. 28, 29 As pro-TAME activates the SAC in an APC/C-dependent manner, without chromosome misalignment at metaphase, it could be reasoned that the reduction in APC/C ligase activity in TIF1g knockdown cells similarly activates the SAC through the stabilization of multiple APC/C substrates. In accordance with this hypothesis, Cdc20, cyclin B1, Aurora A and PLK1 are all elevated in TIF1g knockdown cells (Figure 3a) . As cyclin-dependent kinase activity has previously been shown to sustain the SAC, 30, 31 it is possible that elevated cyclin expression, and presumably therefore, cyclin-dependent kinase activity in TIF1g knockdown cells also sustains activation of the SAC and prevents metaphase-toanaphase transition. Alternatively, other APC/C substrates elevated in TIF1g knockdown cells might similarly promote chromosome misalignment and activate and/or sustain the SAC by targeting SAC components through post-translational modification or protein-protein interaction. Indeed, Bub1 and BubR1 are both APC/C substrates 32, 33 and are activated and elevated following TIF1g knockdown (Figures 5b and c) . Pertinent to this idea, transgenic overexpression of Bub1 in mice gives rise to metaphases with misaligned chromosomes, aneuploidy and tumor formation 34 whereas expression of an acetylated BubR1 mimetic mutant inhibits the APC/C-mediated degradation of BubR1 and leads to a delay in anaphase onset. 33 Consistent with our observations that TIF1g modulates APC/C-Cdc20 activity, TIF1g binds to the APC/C preferentially in mitosis and S phase, and binds to Cdc20 exclusively in mitosis ( Figure 2) . Interestingly, TIF1g binding to the APC/C was unaffected by Cdc20 knockdown, suggesting that TIF1g, binds proportionally to more APC/C holoenzyme than Cdc20 (Figure 2d ). Further analyses revealed that TIF1g is associated with the APC/C-MCC in SACactivated cells, but loses the ability to bind the APC/C once the SAC had been satisfied (Figure 2b ). This observation suggests that TIF1g might participate actively in SAC inactivation by promoting the APC/C-mediated degradation of substrates before anaphase that maintain SAC activation. Taken together the data presented herein suggest that TIF1g associates with the APC/C holoenzyme, active APC/C-Cdc20 complexes, and the APC/C-MCC, and as such participates in the regulation of APC/C-Cdc20 complexes during mitosis.
It has been reported that the TGF-b antagonist, SnoN, is a critical target for APC/C-Cdh1-mediated degradation in TGF-bstimulated cells. 35, 36 As we have determined that TIF1g associates specifically with the Cdc20-bound form of the APC/C, and not the Cdh1-bound form (Figure 1) , these data suggest that TIF1g does not promote the APC/C-dependent degradation of SnoN in TGF-bstimulated cells. However, as APC/C-Cdc20 has recently been implicated in regulating presynaptic axonal differentiation programmes, 37 it is possible that TIF1g-APC/C-Cdc20 complexes could participate in TGF-b signaling pathways that coordinate cell cycle exit and cellular differentiation. 38 In conclusion data presented here demonstrate a role for TIF1g in regulating APC/C function in mitosis. We propose that TIF1g associates specifically with the APC/C to promote the temporally coordinated destruction of APC/C substrates and progression of cells through mitosis.
MATERIALS AND METHODS Antibodies
The anti-Cdc20, APC1, APC4, APC6, APC8, cyclin A, cyclin B1, PLK1 anti-Myc and phospho-Histone H3 (serine-10) antibodies were from Santa Cruz (Santa Cruz, CA, USA). The anti-Cdh1 antibody was from Thermo Fisher Scientific; the anti-b-actin, anti-a-tubulin and vinculin antibodies were from Sigma-Aldrich (Gillingham, UK); the anti-histone H3 antibody was from Millipore (Watford, UK); the anti-Bub1 and anti-Aurora A antibodies were from Abcam (Cambridge, UK); the anti-Bub3, anti-BubR1 and NEK2 antibodies were from Becton Dickinson (Oxford, UK); the anti-APC15 antibody was from Sigma-Aldrich; and the anti-APC3 antibodies were from Becton Dickinson or CR-UK (London, UK). Anti-APC5, APC4, APC7 and APC11 antibodies have been described previously. 4, 29 The rabbit polyclonal against TIF1g was raised against an N-terminal protein fragment (residues 1-392). Anti-mouse and anti-rabbit HRP antibodies were from Dako (Cambridge, UK). Alexa À 488 and À 555 fluorophores were from Life Technologies (Paisley, UK).
Plasmids APC/C subunits, UbcH4, UbcH5, UbcH10, Cdc20, cyclin A and TIF1g were cloned into pGEX4T-1 for bacterial expression. pcDNA3-cyclin A and pcDNA3-cyclin B1 were used for in vitro transcription/translation. pCS2-TIF1g in mitosis GG Sedgwick et al FLAG-TIF1g construct was used for in vitro and mammalian expression. Myc-tagged Cdc20 and Cdh1 constructs were from addgene.
Cells and treatments
HeLa cells were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 8% fetal calf serum and 2 mM L-glutamine (Life Technologies) and cultured at 371C in humidified incubators supplied with 5% CO 2 . Cells were arrested in prometaphase by treatment with 200 ng/ml nocodazole for 20 h and collected by shakeoff. G1 cells were collected 3 h after nocodazole release, and remaining mitotic cells were removed by shake-off. Cells were synchronized at the G1-S border by double thymidine block (2.5 mM). G2 cells were obtained by release from double thymidine block for 8 h followed by mitotic shake-off. 39, 40 Immunoprecipitation and GST pull-down Cells were lysed using immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 0.825 M NaCl, 1% (v/v) NP-40) and clarified by sonication and centrifugation. Immunoprecipitation was then performed as described previously. 41 L-a-[ 35 S]-methionine-labeled TIF1g was expressed in vitro using a TNT T7 Coupled Reticulocyte Lysate System (Promega, Southampton, UK) according to the manufacturer's guidelines. In vitro GST pulldown assays using GST, GST-APC/C and GST-Cdc20 proteins were then performed using established protocols. 42 
SDS-PAGE and western blotting
Whole-cell protein extracts were prepared in denaturing buffer (9 M urea, 150 mM b-mercaptoethanol, 50 mM Tris-HCl, pH 7.4). Extracts were clarified by sonication, and protein concentrations determined by Bradford assay (Bio-Rad, Hemel Hempstead, UK). Proteins were separated by SDS-PAGE in the presence of 100 mM Tris, 100 mM Bicine and 0.1% (w/v) SDS. Proteins were then transferred onto nitrocellulose membranes (Pall, Portsmouth, UK), before being blocked in Tris-buffered saline containing 5% (w/v) dried milk powder and 0.1% (v/v) Tween 80 and incubation with the appropriate antibodies. Antigens were visualized by enhanced chemiluminescence.
RNA interference and transfections
The sequences of the siRNA oligonucleotides, purchased from Life Technologies, were 5 0 -CCUGCAUCUAGAAAGUGAAdTdT-3 0 (TIF1g-1i), 5 0 -GCGACUGAUUACUUUCCAGdTdT-3 0 (TIF1g-2i), 5 0 -GGAAAUAGCCGAGAG GUAAdTdT-3 0 (APC3), 5 0 -GUCUGGUCUAAGUUUCUUUdTdT-3 0 (APC15) and 5 0 -CGUACGCGGAAUACUUCGAdTdT-3 0 (control). The BubR1 siRNA used was a Dharmacon on target plus SMARTpool (Thermo Fisher Scientific). SiRNAs were transfected using Oligofectamine (Life Technologies) as described previously. 41 HeLa cells were transfected with a siRNA-resistant FLAG-tagged TIF1g expression construct using Lipofectamine 2000 (Life Technologies). FLAG-TIF1g was rendered insensitive to TIF1g-1i siRNA by the introduction of two silent mutations: 5 0 -CCUGCAUCUGGAGAGUG AAdTdT-3 0 .
Mass spectrometry
Immunoprecipitates isolated on Protein G Sepharose beads were separated by SDS-PAGE and stained with Coomassie Brilliant Blue (Sigma-Aldrich). Protein bands were excised and subject to treatment with 10 mM dithiothreitol and then 50 mM iodoacetamide. Bands were dried then subject to treatment with trypsin (Promega). Tryptic peptides were analyzed by positive electrospray ionization/mass spectrometry, using a Thermo Fisher Scientific LCQ DECA XP Plus ion trap as described previously. 14 Mass spectrometry/mass spectrometry raw data were searched against a non-redundant human protein database using TurboSEQUEST, as part of the BioworksBrowser 3.1 software suite (Thermo Fisher Scientific).
Video microscopy
Live-cell imaging was performed using a Deltavision core microscope (Applied Precision, Preston, UK) equipped with an incubation chamber maintained at 37 1C in an atmosphere of 5% CO 2 . Videos were acquired at 7-min intervals using a magnification objective of Â 40 and Softworx software (Applied Precision). APC/C ligase assays APC/C complexes were immunoprecipitated from cells using anti-APC3 mAb and protein G sepharose. APC/C ubiquitin ligase activity was assayed as described 4 and resolved by SDS-PAGE. Gels were then dried and visualized by autoradiography.
Confocal microscopy
Cells were seeded onto poly-L-lysine-coated glass slides and fixed and permeabilized with methanol cooled to À 20 1C. Slides were then incubated for 1 h at room temperature in blocking buffer (2% (v/v) fetal calf serum in phosphate-buffered saline (PBS)), and then incubated for 2 h with the primary antibody diluted in blocking buffer. Slides were then washed in PBS, and incubated for 2 h with secondary antibody diluted in blocking buffer. After further washing in PBS, slides were mounted in Vectashield containing DAPI (Vectorlabs, Peterborough, UK). Cells were observed and images were acquired using a Zeiss LSM510-Meta laser scanning confocal microscope (Cambridge, UK).
Fluorescence-activated cell sorting analysis
Cells were fixed in 70% (v/v) ethanol for 1 h, and then washed with PBS before permeabilization in PBS containing 0.25% (v/v) Triton X-100. After washing with 1% (w/v) bovine serum albumin (BSA) in PBS, cells were incubated with an anti-phosphohistone H3 (Ser10) polyclonal antibody in 1% (w/v) BSA in PBS for 1.5 h at room temperature. Samples were then washed twice with 1% (w/v) BSA in PBS, and incubated for 1 h with a fluorescein isothiocyanate-conjugated-anti-Rabbit antibody diluted in 1% w/v BSA in PBS. After washing with PBS alone, cells were resuspended in PBS containing propidium iodide (25 mg/ml) and 0.1 mg/ml of RNAse A, and left at room temperature for a further 1 h. Cell cycle analysis was then carried out using a Coulter XL-MCL flow cytometer (Beckman-Coulter, High Wycombe, UK).
